[Complication of topoisomerase II inhibitor-related acute promyelocytic leukemia with t(1;10) (q21;q26) in a patient with Sézary syndrome].
A 74-year-old man was diagnosed as having Sézary syndrome in 1999. Treatment with combination chemotherapy could not completely control both the erythroderma and Sézary cells. However, treatment with oral administration of etoposide was able to maintain the patient in a good condition for about 4 years. In June 2004, he developed topoisomerase II inhibitor-related acute promyelocytic leukemia. Chromosomal analysis demonstrated abnormalities of t(1;10) (q21;q26) and t(15;17) (q22;q12) in 17 of 20 cells. Despite treatment with ATRA and combination chemotherapy, the patient died of brain hemorrhage.
Miyoshi
Natsuki
N
Department of Internal Medicine, Hiroshima City Hospital.
Noda
Masaaki
M
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D005047:Etoposide / Q000009:adverse effects*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced*; D008297:Male; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects*; D012751:Sezary Syndrome / Q000150:complications* / Q000188:drug therapy; D012878:Skin Neoplasms / Q000150:complications* / Q000188:drug therapy
D000972:Antineoplastic Agents, Phytogenic; D019384:Nucleic Acid Synthesis Inhibitors; D005047:Etoposide